Category Archives: FDI

The new pharma FDI policy undermines Indian generics, which may make drugs more expensive

By relaxing brownfield pharma FDI norms, the government is making way for multinational corporations to take over ‘Make in India’ generics companies. By Leena Menghaney, The Scroll | June 28, 2016 The Union government’s decision to allow up to 74% … Continue reading

Posted in FDI, Generics, HIV/Aids, Uncategorized | Leave a comment

From think tank to trade reports – IP on the boil, again

Source: Business Line MUMBAI, OCT. 26:   Close to 10 years after the Indian Patents Act was amended in January 2005, discussions around intellectual property are on the boil again. Last week, the Government set up a think tank to draft … Continue reading

Posted in FDI, IP Rights, IPR policy, Out of Cycle Review (OCR), Patents, Sec 3 (d), US pressure on India, USTR 301 report | Tagged | Leave a comment

US pharma gets a booster shot

Source: Business Line Thanks to the India-US Intellectual Property Working Group. Here’s how — and why this is bad news for India’s poor Prime Minister Narendra Modi’s first official visit to the US included several meetings with industry representatives and … Continue reading

Posted in BRICS, Compulsory Licensing, FDI, Generics, Innovation, IP Rights, IPR policy, Patent examination system, Patent Term Extension, Pricing, US pressure on India, USTR 301 report, WTO | Tagged , , | Leave a comment

EU keen to resume FTA negotiations with India at the earliest

Source: Firstpost Mumbai: Hoping for an early resumption of the stalled negotiations on free trade agreement (FTA), European Union ambassador Joao Cravinho has said it will require a lot of “give and take” before the two sides arrive at an … Continue reading

Posted in EU-India FTA, FDI, IP Rights, Trade Agreements | Leave a comment

F.D.A. Approves Pill to Treat Hepatitis C

Source: New York Times Tom Espinosa, a building inspector in Oakland, Calif, has tried the existing drugs for hepatitis C and some experimental ones, without success. THOR SWIFT FOR THE NEW YORK TIMES The Food and Drug Administration on Friday … Continue reading

Posted in FDI, Hepatitis C, HIV/Aids, IP Rights, Patent examination system, Patents, Pricing, Right to Health | Tagged , | Leave a comment

Don’t rush into trade agreements, Chidambaram warns

Source: Times of India NEW DELHI: It was supposed to be a brainstorming session convened by Prime Minister Manmohan Singh to discuss India’s trade engagement with the rest of the world. But it was overshadowed by the warning sounded by finance minister P Chidambaram against hasty signing … Continue reading

Posted in Asean, EU-India FTA, FDI, Investment treaties, IP Rights | Leave a comment

EU-India FTA: Unless everything is agreed nothing is agreed, says panel

Source: Zeenews New Delhi: The proposed free trade agreement between India and EU is unlikely to move forward unless the insurance sector is further opened up by New Delhi, hinted a visiting European Parliament delegation Tuesday. A seven-member team of … Continue reading

Posted in EU-India FTA, FDI, IP Rights, IPR Enforcement, Patents | Tagged | Leave a comment